Dursun, Ali Doğan

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14411/6899
Name Variants
Dursun, Ali D. D.
D. Dursun
D.,Ali Dogan
Dursun A.
A., Dursun
Dursun, Ali
Ali Doan
Dursun, Ali Dogan
Dursun, A. D.
A.,Dursun
Dursun,A.D.
D., Ali Doğan
Dursun, Ali Doğan
D.,Ali Doğan
A.D.Dursun
Ali Doğan, Dursun
A. D. Dursun
Dursun, Ali D.
Ali Dogan, Dursun
D., Ali Dogan
Job Title
Doçent Doktor
Email Address
ali.dursun@atilim.edu.tr
Main Affiliation
Basic Sciences
Status
Website
ORCID ID
0000-0001-9056-0025
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
AAH-7617-2019

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
18
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
1
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
1
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
1
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
1
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
2
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
1
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
This researcher does not have a Scopus ID.
Documents

71

Citations

545

Go to WoS profile
Scholarly Output

46

Articles

43

Views / Downloads

290/2111

Supervised MSc Theses

1

Supervised PhD Theses

0

WoS Citation Count

248

Scopus Citation Count

268

Patents

0

Projects

0

WoS Citations per Publication

5.39

Scopus Citations per Publication

5.83

Open Access Source

29

Supervised Theses

1

JournalCount
International Journal of General Medicine4
Drug Design, Development and Therapy3
Medicina3
Sakarya Tıp Dergisi2
Journal of Updates in Cardiovascular Medicine2
Current Page: 1 / 7

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2021 - 20242
Reset filters

Settings

Subject: Pregabalin

Scholarly Output Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Effects of Pregabalin on Kidney Tissue in Spinal Cord Ischemia Reperfusion Injured Rats;
    (Gazi Universitesi, 2021) Ceran,E.U.; Inan,N.; Kucuk,A.; Ozer,A.; Dursun,A.D.; Tosun,M.; Arslan,M.
    Objectives: The purpose of this study was to investigate the possible protective effects of low and high dose pregabalin that was administered in rat in a spinal cord ischemia-reperfusion (I/R) study model. Material and Method: We used 24 Wistar albino rats as subjects in our study. They were divided into 4 groups; randomized Control (C group), I/R (I/R group), I/R-low dose (30 mg/kg) pregabalin (I/R-LP group) and I/R-high dose (200 mg/kg) pregabalin (I/R-HP group). All groups have undergone a laparotomy intervention under anesthesia. In I/R group, a cross clamp was placed in the abdominal aorta just after the laparotomy for 120 minutes (to cause spinal cord ischemia injury) and then reperfusion was achieved by opening the vascular clamp. At the end of the study, kidney tissue was obtained for determining total oxidant status (TOS) and total antioxidant status (TAS) levels, histochemical and immunohistochemical determination. Results: Total Oxidative Status (TOS) enzyme activity was significantly higher in I/R group when compared to the control, I/R-LP and I/R-HP groups. Likewise, Total Antioxidant Status (TAS) enzyme activity was remarkably higher in I/R group when compared with the C, I/R-LP and I/R-HP groups. VEGF staining has yielded no expression in renal tissues. In microscopical analysis of the tissue slides which were immunohistochemically stained with p53 antibody, some crucial findings have been established as follows: As p53-expressing cells were not detected in the control group, the presence of p53-expressing cells were clearly identified at different intensities in several bowman capsules in the I/R group. However, no expression was detected in general tubules. Interestingly, p53 expression levels were prominently lower in low-dose pregabalin given group and considerably higher in the 200 mg/kg pregabalin administered group, which was more pronounced than the I/R group. Conclusion: Results established from the current study suggest that pregabalin given at different doses may have a partial protective effect in kidney tissues of rats undergone experimental spinal cord IR injury. ©Copyright 2021 by Gazi University Medical Faculty
  • Thumbnail Image
    Article
    Citation - WoS: 2
    Citation - Scopus: 2
    Chronic Pregabalin Treatment Reduced Anxiety, and Acute Pregabalin Treatment Increased Depression-Like Behaviors in Rats
    (Bmc, 2024) Caliskan, Hasan; Akat, Firat; Dursun, Ali Dogan; Zaloglu, Nezahet
    BackgroundPregabalin is an antiepileptic drug that binds to the alpha-2/delta unit at presynaptic voltage-dependent calcium channels. We aimed to investigate the effect of acute and chronic pregabalin administration on anxiety and depression-like behaviors.MethodsFifty-six male Wistar albino rats were divided into seven groups: control, vehicle, and five different dose groups (5, 10, 30, 60, and 100 mg/kg). Pregabalin was administered for two weeks. Depression-like behaviors were evaluated by Forced swimming test. Anxiety-like behavior (ALB) was evaluated by Open field test (OFT), Elevated Plus Maze (EPM), and light-dark box. Subjects underwent the forced swimming test (FST) after the first dose, while the open field test (OFT), elevated plus maze (EPM), and light-dark box (LDB) were performed after two weeks of treatment. Further sucrose preference test was conducted to evaluate anhedonia until the end of the experiment.ResultsIn the forced swimming test, depression-like behaviors increased after acute single-dose administration of 10, 30, 60, 100 mg/kg pregabalin. According to OFT results, chronic 100 mg/kg pregabalin showed anxiolytic effects by decreasing grooming, and freezing behaviors. In addition, 100 mg/kg chronic pregabalin administration significantly increased the time spent in the central region, the number of entries to the center, and the unsupported rearing number without causing any change in locomotor activity. According to EPM results, both chronic 60 and 100 mg/kg pregabalin treatments showed anxiolytic effects by increasing open arm time and head dipping behavior. In addition, 60 and 100 mg/kg chronic pregabalin administration significantly decreased stretch attend posture. All pregabalin administrations between 5 and 100 mg/kg displayed anxiolytic effects in the LDB. Sucrose preference was above 65% for the duration of all experiments and subjects did not show anhedonia.ConclusionAcute pregabalin treatment triggered depression-like behaviors. Anhedonia, which may be associated with depression, was not observed during chronic treatment. Moreover, chronic treatment with pregabalin revealed potent anxiolytic effects in different behavior patterns and doses for all tests of unconditional anxiety. In particular, 100 mg/kg chronic pregabalin administration decreased anxiety-like behaviors in all experiment setups. Although the anxiolytic effect was demonstrated in chronic treatment, acute treatment of pregabalin induced depression-like behaviors, and thus in clinical practice should be done with caution, especially in patients with anxiety-depression comorbidity.